| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Patients across the U.S. will soon have access to a new cervical cancer test collected from the comfort of their own home—no stirrups, speculum, or in-person doctor’s visit needed. The life sciences company Waters is partnering with Quest Diagnostics to make Waters’ Onclarity HPV Self-Collection Kit available for use at home. The partnership, announced Tuesday, will begin making self-collection kits available in early 2027.
We’re taking a closer look at new research highlighting the risks of tick-borne diseases. A study by Quest Diagnostics, published in JAMA Network Open, found that nearly one in three patients with antibodies for Lyme disease also had antibodies for at least one other tick-borne pathogen. Joining us to break down the findings and explain what they mean for diagnosis and treatment is Dr. Emily Schindler, Medical Director of Infectious Disease and Immunology at Quest Diagnostics.
Quest Diagnostics calls for passage of RESULTS Act as survey shows 96% of voters value lab testing. Claire Wallace,Senior Writer,Informa Markets – Engineering Quest Diagnostics is calling on Congress to pass the RESULTS Act before scheduled Medicare laboratory payment cuts take effect in January 2027, citing new survey data showing overwhelming public support for protecting access to diagnostic testing and concerns about the flawed rate-setting process under current law.
The ctDNA liquid biopsy demonstrated 100% specificity and outperformed standard CEA testing in residual specimen analysis. A study published in The Journal of Molecular Diagnostics shows that the Haystack MRD test accurately detects residual and recurrent colorectal cancer, demonstrating clinical performance in patient specimens from the DYNAMIC clinical trial series. The study also validated the test’s analytical performance across 23 solid tumor types.
Despite the surge of people who embraced healthier lifestyles amid the new perspectives they’d gained during the pandemic, drug use still remains significant among U.S. workers. Recent data analysis by testing company Quest Diagnostics found that nearly 20 percent of employees generated positive results for a range of illicit substances in 2025, “potentially reflecting recurring or chronic drug use.”
A positive Lyme disease antibody result may signal a need to consider other tick-borne pathogens, according to a study of 193,260 individuals tested at Quest Diagnostics. In the U.S. Northeast, 31.1% of people positive for B. burgdorferi also tested positive for at least one of those other three pathogens, Yonghong Li, PhD, of Quest Diagnostics in San Juan Capistrano, California, and colleagues reported in a JAMA Network Open research letter.
With CMS poised to release clinical lab payment rates with statutorily mandated reductions of up to 15%, Quest Diagnostics is highlighting a survey finding that consumers across party lines view lab tests as critical to their care and is urging Congress to pass the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act before the cuts kick in on Jan. 1.
With the US Food and Drug Administration (FDA) recently clearing two blood-based Alzheimer’s tests and additional regulatory clearances expected in the near future, the market for such assays is an increasingly crowded one. he clinical laboratory firms Quest Diagnostics and Laboratory Corporation of America offer both the FDA-cleared Roche and Fujirebio tests and their own laboratory-developed Alzheimer’s blood tests. “There is a little bit of difference in the performance of the tests,” said Michael Racke, medical director for neurology at Quest. He noted, for instance, that studies have indicated mass spectrometry (used by C2N in PrecivityAD2) may offer better measurement of plasma Aβ 40/42 than immunoassays, a finding that he said influenced Quest’s decision to use mass spec for its AD-Detect Alzheimer’s LDT. Different immunoassays have also shown differences in performance, he said.
Labcorp and Quest Diagnostics see solid growth on the horizon for laboratory companies as health systems try to blunt financial headwinds and patients seek more on-demand services. After acquiring lab assets from systems such as Minneapolis-based Allina Health, Columbus, Ohio-based OhioHealth, Franklin, Tennessee-based Community Health Systems and Fort Wayne, Indiana-based Parkview Health, the two dominant national commercial laboratory companies have set their focus on broadening test menus and direct-to-patient offerings.
Quest Diagnostics announced that Apple Health app users across most of the United States will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function.
Medicare’s expansion of coverage for A1c for diabetes screening in 2024 was followed by significant increases in use of the test and detection of prediabetes, new data showed. The researchers compared laboratory data from Quest Diagnostics from January 1, 2022, to September 30, 2023, with data from the same period in 2024-2025. “This is the first study I’m aware of that specifically looks at how the testing patterns changed after Medicare adopted the rule,” said co-investigator Jason Ng, MD, clinical professor of medicine in the Division of Endocrinology and Metabolism at the University of Pittsburgh Medical Center in Pittsburgh.
Cardiologist Dr. Marc Penn joins Good Day DC. to discuss how new, advanced testing can reveal hidden cardiovascular risks that standard cholesterol panels often overlook.
Now, for the first time, you can test your biological age when you get your next round of blood work. Humanity Health Inc. and Quest Diagnostics are launching “Humanity Biological Age.” This test is available in the U.S. via questhealth.com. It’s a $29 add-on to certain existing Quest blood panels (like the Elite Health Profile or Men’s/Women’s Comprehensive Health Profiles) with no extra blood draw needed.
More than 860 North Carolinians have tested positive for Cyclospora this summer. They join thousands of Americans nationwide testing positive for the parasite at levels the country has never seen before. Two North Carolina cases have now been tied to a multistate outbreak involving shredded lettuce. A Cyclospora diagnosis requires a stool sample. In North Carolina, many of those samples during this summer’s historic rise in cases have been sent to Quest Diagnostics. “It’s been a busy summer, to say the least,” said Dr. Ann MacIntyre, senior medical director for infectious diseases at Quest Diagnostics.
Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. On a laboratory table that normally sits empty, hundreds of feces samples are arranged in stacks six vials high. They’ve traveled by ground and plane, across seven different eastern U.S. states, for one purpose: to be tested for parasites, including cyclospora. And they’re coming faster than scientists here can test them. At Quest’s Clifton lab, workers are putting in extra hours.
Women with vaginosis are around three times as likely to also test positive for gonorrhea, chlamydia or other bacterial sexually transmitted infections, a new study says. The study results confirm guidance from the U.S. Centers for Disease Control and Prevention that women being treated for bacterial vaginosis should be tested for STIs, which can present with similar symptoms, researchers said in the journal O&G Open. "STIs can lead to serious reproductive and other health complications when left undetected and untreated,” senior researcher Dr. Damian Alagia said in a news release.
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.'
As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. "The problem is real," agreed Thomas Koch, senior VP and global head of research and development at Quest Diagnostics, adding that liquid biopsy "is a very fast-growing field with many players." Beyond the rise in demand for testing, test complexity has also contributed to the workforce shortage. Liquid biopsy tests often feature workflows involving dozens of steps along with sophisticated chemistries, hardware, software, and data analysis tools. "It's an entire ecosystem that is a little different from the standard clinical laboratory where you do, say, a calcium test, and then report it out," said Quest's Koch.
Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates. Shares of the New Jersey-based company rose about 5% in premarket trading following the results. Demand for the company's diagnostic testing services was strong across its physician, hospital and consumer channels, Quest said. The results were "well above what was widely expected," Barclays analysts said.
Framing sexually transmitted infections (STIs) as a large-scale problem often obscured by percentages, Damian Alagia, III, MD, MS, MBA, FACS, Chief, Hospital and Health Systems, and Senior Medical Director, Advanced Diagnostics / Women's Health, Quest Diagnostics, argued that universal, non-judgmental testing is central to reaching reproductive-age women. Alagia said absolute figures convey the scale more effectively than rates, noting over 1.5 million patients annually with chlamydial infections, some 190,000 patients with syphilis, and nearly 4,000 babies with congenital syphilis, in 2024 data from the Centers for Disease Control and Prevention (CDC).
Nearly one in five American workers tested positive for drug use in long-term screenings last year, driven by a rise in cannabis consumption that is forcing companies to reevaluate their hiring practices. According to new data from Quest Diagnostics, 19.1 percent of workers screened via hair analysis in 2025 returned a positive result, representing a 46 percent increase from 2021. Marijuana accounted for 52.5 percent of those positive hair tests.
Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets administrative friction from multi-biomarker orders and dense reports by reducing ordering steps, accelerating account setup, and returning more usable results inside routine EHR workflows.
The Quest Diagnostics Foundation said this week that it has awarded nearly $5 million in grant funding to four Miami-area non-profits to improve chronic and maternal health outcomes. With the funding, which was granted to the Florida International University Foundation, Urban Health Partnerships, The Health Council of South, and US Hunger, the Quest Diagnostics Foundation aims to expand healthcare access in the area, including through no-cost lab testing.
Quest Diagnostics said Wednesday that its Haystack MRD test has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for use in identifying residual or recurring disease in patients with a range of solid tumors. With the approval, Haystack MRD is now available for patient testing in all 50 states and the District of Columbia. Quest launched the circulating tumor DNA liquid biopsy test in late 2024.
A hard-to-kill species of pneumonia-causing bacteria that has traditionally been found mainly in hospitals is now spreading in U.S. community settings, according to research that could help lead to new treatments. To learn more about its patterns of spread, researchers analyzed multidrug-resistant Klebsiella pneumoniae detected in urine and blood samples from more than 2,000 people in 42 states at local offices of Quest Diagnostics, a leading provider of outpatient laboratory testing.